Podcasts about leqembi

In this episode of Living With Alzheimer's, Christoph interviews Bill Reznak and Dr. John McGuire who host the Friends with Medical Benefits podcast.They discuss how two high school buddies reunite to support each other through their medical journeys. Bill, a colon cancer survivor, and Dr John, recently diagnosed with early-onset Alzheimer's, describe how their reunion led to their podcast about the ups and downs of aging and illness.Dr John describes the difference between “early-onset” Alzheimer's and “early stage” Alzheimer's. And he discusses the two intravenous treatments that have become recently available to help slow dementia progression: Leqembi and Kisunla.They discuss their individual prognoses and how they're supporting each other through their medical journeys. And they wrap up their conversation with Bill and John's most repeated theme: Get diagnosed early!

What if amyloid is only the match, tau is the brush fire, and neuroinflammation is the wildfire that causes the most damage in Alzheimer's disease?In this episode of Happy & Healthy with Amy, Amy explains why researchers are paying closer attention to neuroinflammation, what may be keeping the brain's immune system stuck in the “on” position, and why midlife is such an important window for protecting your brain.You'll learn how sleep, blood sugar, chronic stress, infections, oral health, and social connection may all influence the conditions that make the brain more—or less—flammable.What to Listen For[00:00] Why amyloid may be the match—but neuroinflammation is the wildfire. [02:30] What the Cochrane review found about anti-amyloid drugs. [04:30] Why timing matters in Alzheimer's disease. [07:00] Is neuroinflammation a side effect—or a driver? [09:00] Why inflammation itself is not the villain. [11:00] Meet microglia: the brain's immune cells. [14:00] Why gum disease matters for Alzheimer's risk.[18:00] The shingles vaccine and dementia risk. [22:00] Blood sugar, insulin resistance, stress, and sleep. [29:00] How to make your brain less “flammable.” Neuroinflammation may be one of the most important pieces of the Alzheimer's prevention puzzle because it connects so many things we often treat separately: sleep, stress, blood sugar, oral health, infections, diet, and connection.Listen to the full episode to understand what may be making your brain more “flammable,” then download the free RESTORED Protocol so you can choose one simple, evidence-based next step for protecting your brain.Mentioned in The EpisodeDownload the RESTORED ProtocolDownload The First Steps Guide for supporting a parent after Alzheimer's diagnosisRelated EpisodesAlzheimer's Prevention: What the Cochrane Review MeansAlzheimer's Drugs: Why Amyloid Removal May Not Be EnoughGum Disease, Menopause & Your Alzheimer's RiskSourcesRESOURCES:Book a FREE Discovery Call with AmyDownload After Mom's Alzheimer's Diagnosis: The First 8 Things to Know and learn how to support her with more calm, clarity, and confidence.Download the RESTORED Protocol: Eight Essential Protective Factors to Build an Alzheimer's-Resistant BrainSchedule your Breakthrough Roadmap session with AmyFollow Amy on Instagram @amylangcoaching  and on Facebook @amylangcoachingSubscribe to Amy's YouTube channel @happyandhealthywithamy

Läkaren Moa Wibom och forskaren Henrik Zetterberg. svarar i vårt nya korta poddformat Våga Fråga. I det här avsnittet svarar Moa Wibom bland annat på följande frågor: - Regionerna har sagt nej till bromsmedicinen Leqembi. Går det att ompröva? - Varför är ni läkare och forskare så positiva till att Leqembi bör godkännas men inte politikerna? - Hur är effekten av bromsande läkemedel om man tar dem i 3-4 år? - Det finns ett annat bromsande läkemedel – Kisunla – som är goidkänt i både Europa och USA. Är chansen större att detta läkemedel blir godkänt? - Vad krävs för att få chansen att pröva dessa läkemedel den dagen de blir godkända? - Det sägs att man kan åka till ett sjukhus i Finland för att få dessa injektioner. Berätta mer? Moa Wibom svarar utförligt på dessa och många andra frågor.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of transformative events shaping the industry landscape, from scientific breakthroughs to regulatory shifts and strategic realignments. Eisai's progress with its Alzheimer's treatment, Leqembi, marks a significant milestone in addressing one of the most challenging neurological disorders. With a sales forecast of $900 million, this development underscores the growing demand for effective Alzheimer's treatments. Eisai's partnership with Biogen plays a crucial role in this context, aiming to provide a solution to a disease that has long eluded effective therapeutic intervention. This collaboration highlights the intricate interplay between scientific innovation and strategic alliances in tackling complex health challenges. Biogen's recent data on Alzheimer's disease advances our understanding of neurodegenerative disorders by reinforcing the tau hypothesis alongside longstanding amyloid-beta research. This insight opens new avenues for therapeutic interventions targeting tau proteins—a potentially pivotal shift given prior limited success with amyloid-centric approaches. Denali Therapeutics may benefit from this paradigm shift thanks to its proprietary technology that enhances central nervous system drug delivery—a crucial factor for effective tau-targeting therapies. Concurrently, organizational restructuring at Novartis reflects broader industry trends. As companies increasingly focus on optimizing operations and honing in on core therapeutic areas, Novartis's strategy to streamline its biomedical research arm could potentially impact innovation timelines and resource allocation. This move is indicative of a wider industry shift aimed at enhancing research efficiency and maintaining competitive edges in a rapidly evolving market. Regulatory updates continue to be pivotal, as seen with the U.S. Supreme Court's decision to temporarily restore telehealth access to the abortion pill mifepristone. This ruling not only underscores the intersection between healthcare access and legal frameworks but also highlights potential implications for patient accessibility to medications across the U.S. Meanwhile, AstraZeneca's Imfinzi received swift regulatory endorsement from NICE for perioperative use in stomach cancer just 17 days post UK approval. Such rapid endorsements are crucial in expanding treatment options and improving patient outcomes, particularly in oncology where timely interventions can be life-saving. In market dynamics, Novo Nordisk's Wegovy pill has experienced its first decline in total prescriptions, as tracked by Fierce Pharma through their new oral GLP-1 tracker. This development suggests shifting preferences among clinicians and patients within the competitive landscape of weight management therapies. It points to an environment where continuous innovation and adaptation are necessary to maintain market presence. Biopharmaceutical pipelines are increasingly dominated by biologics, presenting both opportunities and challenges. A report highlights manufacturing complexities that pose hurdles for new product launches, emphasizing the industry's shift from small molecules to biologically-derived therapies. As demand grows, advancements in manufacturing technologies and processes become essential to meeting these needs effectively. Aardvark Therapeutics' decision to unblind its phase 3 Prader-Willi syndrome study data following an FDA-imposed hold illustrates the regulatory hurdles that can occur during drug development. These holds often delay critical data analyses but also present opportunities for reevaluating trial strategies, ensuring that patient safety remains paramount. Aardvark Therapeutics faces regulatory challenges as its Prader-Willi syndrome trials encounter an FDA-imposed hold due to cardiac safety concerns. These developments highlight both scientific promise and the stringent safety standards essential within drug development processes. Technological innovation is reshaping drug discovery efforts through targeted protein degradation—a method allowing researchers to address previously "undruggable" targets. This approach signifies a potential revolution in developing novel therapeutic modalities across various diseases, highlighting the industry's capacity for groundbreaking advancements. On the policy front, bipartisan lawmakers have reintroduced legislation aimed at preventing pharmacy benefit managers from owning retail pharmacies. This legislation seeks to address conflicts of interest that could impact drug pricing and access, underscoring the ongoing scrutiny on practices affecting healthcare costs. In oncology, Genmab's recalibration of its antibody-drug conjugate pipeline signals competitive pressures within this innovative space where differentiation is key to maintaining market leadership. Similarly, Create Medicines' entry into CAR T-cell therapies—backed by substantial funding—reflects ongoing investment in breakthrough cancer treatments while balancing immediate clinical opportunities with strategic long-term goals. Amidst these transformative developments are broader industry trends involving employment shifts and funding dynamics. Despite workforce reductions like those at Takeda as part of its transformation strategy, there remains strong momentum within sectors such as California's vibrant biotech scene—illustrating resilience amid economic pressures. These stories exemplify an industry characterized by transformation driven by scientific insights into disease mechanisms coupled with regulatory vigilance ensuring patient safety remains paramount throughout all stages—from discovery through commercialization—ultimately striving towards improved patient care outcomes addressing various unmet medical needs worldwide.Support the show

What's the difference between Alzheimer's and dementia—and how can you spot the early signs?In this episode of the Health & Wellness podcast, Sanford Health clinical neuropsychologist, Dr. Nicole Norheim explains the key differences between Alzheimer's disease and other types of dementia, early warning signs to watch for, and why early detection is critical.Learn how memory loss is evaluated, what happens in the brain, and the latest treatment options that may help slow progression. Dr. Norheim also shares practical tips for staying mentally sharp, supporting loved ones, and improving quality of life. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into a range of significant industry updates, spotlighting scientific advancements, regulatory challenges, and strategic movements that are shaping the future of drug development and patient care. The pharmaceutical landscape is often marked by rapid changes, as evidenced by recent reports indicating President Donald Trump's plan to dismiss FDA Commissioner Marty Makary. This potential leadership change is set against a backdrop of controversies during Makary's tenure, including the rejection of Replimune's advanced melanoma therapy, RP1. This therapy was designed as an oncolytic immunotherapy using a genetically modified herpes simplex virus to target and destroy cancer cells. The FDA's rejection of RP1 ignited debate over the agency's decision-making processes, which some critics view as inconsistent and lacking transparency. Such decisions can have profound implications—delaying patient access to critical treatments and affecting company financials and market dynamics. Furthermore, internal discord at the FDA during Makary's leadership period underscores the importance of stable leadership in maintaining efficiency and fostering scientific rigor. Turning to corporate developments, Gilead Sciences has revised its first-year sales forecast for YezTugo, its long-acting PrEP injection for HIV prevention. The company now projects revenues to reach $1 billion, reflecting strong market uptake. This adjustment highlights the growing demand for innovative PrEP solutions as part of broader HIV prevention strategies. Meanwhile, Daiichi Sankyo is grappling with a $610 million profit setback due to an overextension in their manufacturing capabilities for antibody-drug conjugates (ADCs). This situation illustrates the financial risks inherent in scaling production within rapidly evolving therapeutic areas like ADCs, where balancing supply and demand remains critical. In legal news, Capricor Therapeutics has initiated a lawsuit against NS Pharma concerning a breach-of-contract over Deramiocel, a Duchenne muscular dystrophy treatment. With an FDA decision pending, this legal battle underscores the complexities of partnerships and contract compliance in advancing neuromuscular therapies. On the regulatory front, Biogen and Eisai are experiencing delays from the FDA regarding their Alzheimer's drug Leqembi. These regulatory hurdles highlight the complex processes that can impact drug rollout timelines significantly. Odyssey Therapeutics' successful $304 million IPO aims to bolster its autoimmune and inflammatory disease pipeline. This reflects robust investor interest in biotech firms with promising therapeutic candidates addressing high-need areas. In terms of market dynamics, the competition between Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo is reshaping the oral GLP-1 receptor agonist market. A newly launched weekly tracker will monitor prescription trends to provide insights into how these weight-loss solutions are impacting obesity management. Additionally, Johnson & Johnson's efforts to enhance awareness around depression treatment through public health campaigns illustrate how companies are addressing mental health challenges. Advancements in digital health continue with Tether's rollout of medical AI for mobile devices and MedAptus' operational 'command center,' highlighting ongoing innovations poised to transform healthcare delivery by enhancing efficiency and patient engagement. Strategic acquisitions remain a key theme as Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion—a move that expands Angelini's footprint into the U.S. rare neurological drug market. Similarly, Blackstone's $250 million investment in Anagram Therapeutics for cystic fibrosis enzyme replacement therapySupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into an array of dynamic changes and strategic maneuvers within the industry, showcasing how these transformations are shaping the future of healthcare and patient treatment. Starting with regulatory innovation, the FDA's new initiative to facilitate real-time review of clinical trial data is a potential game-changer for drug development timelines. With AstraZeneca and Amgen participating in this pilot program, the industry anticipates a more efficient approval process that addresses issues during trials rather than post-completion. This could significantly reduce the time it takes for patients to access cutting-edge therapies, marking a pivotal shift towards more agile regulatory frameworks. Such initiatives reflect a broader move towards streamlining drug approvals without sacrificing safety and efficacy. Turning to strategic investments, AstraZeneca's renewed commitment to a £300 million investment in the UK, following earlier disputes over drug pricing, signals confidence in resolving these issues favorably. This decision underscores AstraZeneca's dedication to fostering innovation within the UK's life sciences sector. Similarly, Teva Pharmaceuticals' $700 million acquisition of Emalex Biosciences positions it to introduce a new therapy for Tourette syndrome, highlighting efforts to address conditions with limited treatment options. In oncology, GSK is aligning its strategy with industry trends by focusing on cancer therapies. Despite withdrawing from a partnership with Mersana Therapeutics and pausing its mRNA bird flu shot program, GSK aims to channel resources into more promising ventures. This reflects a broader industry focus on oncology due to its high unmet needs and market potential, which companies are eager to capitalize on through innovative treatments. Additionally, Kite Pharma is preparing for potential approval of its next-generation CAR-T therapy for multiple myeloma, representing ongoing progress in personalized medicine approaches aimed at complex diseases like cancer. Furthermore, Pfizer's Elrexfio has shown promising results in multiple myeloma trials, potentially expanding treatment options and reinforcing Pfizer's oncology market position. The competitive dynamics in Alzheimer's treatments are also noteworthy as Biogen and Eli Lilly vie for market share with Leqembi and Kisunla, respectively. This competition highlights complexities in chronic disease management where dosing differences may influence patient decisions. The biotech sector remains robust in fundraising activities despite challenges. Noteworthy is Vivacta's $50 million Series A round and Coultreon's $125 million fundraising effort, indicating strong investor confidence in biotech innovations. These financial injections are vital for advancing ambitious projects that promise transformative impacts on patient care. Strategic acquisitions continue to shape the industry landscape. Chiesi Group's $1.9 billion acquisition of KalVista Pharmaceuticals exemplifies this trend, focusing on expanding rare disease offerings—a niche market with significant unmet needs but fewer competitors. Meanwhile, AbbVie's acquisition option for Kestrel Therapeutics underscores its strategic expansion into targeted cancer therapies, particularly through Kestrel's promising oral pan-KRAS inhibitor. In regulatory scrutiny news, AstraZeneca's camizestrant faces intense evaluation ahead of advisory committee meetings. Such scrutiny ensures that only effective treatments reach the market while emphasizing the rigorous standards required during drug development processes. Lastly, technological integration within pharmaceutical operations is becoming increasingly crucial as companies leverage AI to enhance R&D efficiency and accelerate value crSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into recent significant advancements and strategic maneuvers reshaping the landscape in these dynamic industries. AstraZeneca has made a notable stride with its chronic obstructive pulmonary disease (COPD) drug candidate, achieving remarkable efficacy in Phase 3 trials. This success is particularly significant given the historical challenges in this therapeutic area, where competitors like Roche and Sanofi have struggled to deliver consistent results. AstraZeneca's achievement not only highlights its innovative clinical development strategies but also offers renewed hope for COPD patients who have long awaited more effective treatment options.In a parallel move, AstraZeneca is pioneering in vivo CAR-T cell therapies, showcasing their potential despite safety concerns following a patient death during trials in China. The therapy's ability to eradicate cancer in three out of five patients underscores its promise as a revolutionary treatment for cancer, illustrating the need for ongoing safety evaluations as this technology develops.Meanwhile, Novartis continues to strategically expand its allergy treatment portfolio with a significant $2 billion acquisition of Excellergy. This deal centers around an anti-IgE program poised to potentially replace Xolair, Novartis's leading allergy medication. Such strategic moves underscore Novartis's commitment to remaining at the forefront of allergy therapeutics by harnessing biotechnological innovations to develop next-generation treatments. This acquisition complements existing assets like Xolair, an IgE blocker now approved for treating food allergies across different age groups, aiming to bolster Novartis's competitive edge in allergy therapeutics by providing a broader array of solutions.Otsuka Pharmaceutical is also making waves with its $1.2 billion acquisition of Transcend Therapeutics. This acquisition focuses on an MDMA analog for psychiatric conditions, marking Otsuka's deepening interest in mental health therapeutics and the burgeoning field of psychedelic compounds as viable psychiatric treatments. This move reflects a broader industry trend towards exploring unconventional therapeutic avenues to address complex mental health issues.On the regulatory front, Takeda is undergoing significant restructuring efforts aimed at achieving $1.3 billion in annual savings through reorganization. This reflects a broader industry trend towards optimizing operations to enhance efficiency and maintain competitiveness in an ever-evolving market landscape.In another noteworthy development, Rocket Pharmaceuticals has secured accelerated FDA approval for Kresladi, a gene therapy targeting severe leukocyte adhesion deficiency-1. This approval highlights the growing potential of gene therapies to meet unmet medical needs for rare diseases and sets an important precedent for other companies seeking expedited regulatory pathways for their gene therapy pipelines.In Alzheimer's research, both Eisai and Alzheon have made significant contributions, especially regarding high-risk patient subsets. Eisai presented real-world data on Leqembi at the AD/PD annual meeting, demonstrating safety and efficacy in patients with specific genetic profiles like APOE4 homozygotes. Concurrently, Alzheon provided insights into its candidate's performance in similar cohorts. These findings underscore personalized medicine's growing importance in neurodegenerative disease treatment.Oncology remains a critical area with Merck's announcement of its planned acquisition of Terns Pharmaceuticals for $6.7 billion. Driven by Terns' promising leukemia drug developments, this acquisition exemplifies how major players are diversifying their oncology pipelines to maintain market leadership amid approaching patent expiraSupport the show

Algernon Health CEO Christopher Moreau joined Steve Darling from Proactive to announce the company will open its inaugural brain PET scanning clinic at the HCA Florida University Medical Office Building, located on the campus of HCA Florida University Hospital. The clinic will be operated by Algernon USA LLC, a wholly owned subsidiary, which has signed a five-year lease with an option to renew for an additional five years. The company also plans to expand with multiple clinics across the United States as part of a broader rollout strategy. Moreau highlighted that the facility will be the first of its kind in the U.S. dedicated to brain-specific PET imaging. The clinic will focus on early detection and diagnosis of neurological conditions including Alzheimer's disease, dementia, epilepsy, neuro-oncology indications, and movement disorders such as Parkinson's disease. The site will feature the CareMiBrain system, an FDA-cleared standalone PET scanner designed specifically for brain imaging. Unlike traditional systems, it does not require an integrated CT component, enabling high-quality imaging while reducing patient radiation exposure by approximately 25%. Importantly, brain PET scans used for beta-amyloid plaque detection are covered by Medicare, Medicaid, and private insurance for patients aged 65 and older. This is particularly relevant given the emergence of new Alzheimer's treatments such as Leqembi and Kisunla, both of which require confirmation of amyloid plaque presence—via PET scan or spinal tap—before patients can begin therapy. These developments are helping drive rapid growth in the Alzheimer's diagnostics and treatment market, creating a significant opportunity for specialized brain imaging services. Algernon plans to work closely with neurologists, geriatricians, and primary care providers to build referral networks, while also targeting the 50+ population directly to raise awareness around early detection. The company emphasized that beta-amyloid plaques can develop 15 to 20 years before symptoms appear, reinforcing the value of early screening through cognitive testing, blood biomarkers, and advanced imaging. #proactiveinvestors #algernonpharmaceuticalsinc #cse #agn #otcqb #agnpf #alzheimerdisease #demetia #AlgernonHealth #BrainHealth #MedicalImaging #HealthcareInnovation #PETScan #Neurodegeneration #Biotech #EarlyDetection #ChristopherMoreau #BrainPET #MedicalImaging #HealthcareInnovation #Alzheimers #Dementia #Parkinsons #Neurology #PETScan #EarlyDetection #HealthTech #MedTech #CareMiBrain #Diagnostics #AgingPopulation #Healthcare #Biotech #Innovation #USHealthcare

This interview was brought to you in partnership with Eisai and is part of the Journey to Diagnosis series.Eisai: https://www.eisai.com/index.htmlJourney to Diagnosis: https://beingpatient.com/journey-to-diagnosis/Luke Davis spent four decades as a Dallas attorney — and an active husband, father, youth sports coach and school board member — before subtle memory changes raised concerns. In this Being Patient Perspectives interview, Luke and his wife, Paula Davis, share the early signs of Alzheimer's they noticed first, how they pursued answers, and what helped them move forward.After a primary care visit, Luke underwent cognitive testing, an MRI and an amyloid PET scan that confirmed plaque. In April 2023, just before his 69th birthday, he was diagnosed with early-stage Alzheimer's disease. Luke later learned he carries two copies of the APOE4 gene, a major genetic risk factor for Alzheimer's.Luke and Paula also discuss treatment and support — including Luke's experience with Leqembi (lecanemab) infusions — and how they've leaned on the Alzheimer's Association, community, and practical day-to-day strategies. Their message for newly diagnosed individuals and couples: Alzheimer's is a detour, not a dead end — and Luke is focused on “living with Alzheimer's, not dying from it.”Topics covered: early Alzheimer's symptoms, diagnosis journey, amyloid PET scan, APOE4, Leqembi/lecanemab, caregiving as a spouse, coping after diagnosis, living well with Alzheimer's, advocacy and support.#Alzheimers #EarlyAlzheimers #Leqembi #Lecanemab #APOE4 #Dementia #BrainHealth #BeingPatient---- If you loved watching this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/Follow Being Patient: Twitter: https://twitter.com/Being_Patient_Instagram: https://www.instagram.com/beingpatientvoices/Facebook: https://www.facebook.com/beingpatientalzheimersLinkedIn: https://www.linkedin.com/company/being-patientBeing Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://beingpatient.com/live-talks/

No Comentário Final de hoje, Ricardo Spinosa traz mais detalhes sobre o medicamento Leqembi, recém-autorizado no Brasil, apontado como uma nova esperança no combate ao Alzheimer. O jornalista reforça a importância da informação e destaca o impacto positivo que o remédio pode representar para milhares de famílias brasileiras que convivem com a doença, despertando atenção para os próximos avanços e esclarecimentos sobre o tratamento.#ComentarioFinal #RicardoSpinosa #Saúde #Alzheimer #Leqembi #Medicina #Esperança

No Comentário Final de hoje, Ricardo Spinosa destaca como excelente a autorização da Anvisa para o uso do medicamento Leqembi, indicado para pacientes na fase inicial do Alzheimer. O jornalista explica que o remédio ajuda a retardar o declínio cognitivo e levanta questões importantes: como funciona o tratamento, se o medicamento será importado e quando estará disponível no Brasil, deixando o convite para mais esclarecimentos no próximo Rádio Notícias 1ª Edição.#ComentarioFinal #RicardoSpinosa #Saúde #Alzheimer #Anvisa #Leqembi #Medicina #QualidadeDeVida

Nyheter och fördjupning från Sverige och världen. Lyssna på alla avsnitt i Sveriges Radios app. RÄTTLESE: I en tidigare version av ett inslag i den här sändningen, om att den brittiska regeringen ställer ett ultimatum till den ryske oligarken Roman Abramovich, sa vi felaktigt att den summa som varit fryst motsvarande drygt 300 miljarder kronor. Rätt ska vara att summan motsvarar drygt 30 miljarder kronor. RÄTTLESE: I en tidigare version av ett inslag i den här sändningen om Alzheimerläkemedlet Leqembi, sa vi felaktigt att Tandvårds- och läkemedelsförmånsverket, TLV, bedömer att Alzheimerläkemedlet Leqembi inte är kostnadseffektivt. Det var fel. Rätt är att TLV anser att det finns betydande osäkerhet i hälsoekonomin beträffande läkemedlet.

Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to announce a key clinical milestone, confirming that the first patient has been successfully dosed with intranasal foralumab in the company's Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer's disease (AD). This achievement follows the company's December 12, 2025 announcement that patient enrollment had begun, with first dosing expected imminently. The rapid progression from enrollment to dosing highlights strong site readiness and momentum for the study. The Phase 2 trial is designed to evaluate intranasal foralumab both as a standalone therapy and in combination with FDA-approved anti-amyloid treatments, including lecanemab (Leqembi®) and donanemab. By exploring combination therapy alongside monotherapy, Tiziana aims to assess whether targeting neuroinflammation can provide additive or complementary benefits to existing amyloid-reducing approaches. Elrifi explained that the trial is supported by compelling TSPO-PET imaging data, which demonstrate persistent and widespread microglial activation—a key marker of neuroinflammation—in patients with Alzheimer's disease. Notably, this neuroinflammatory activity has been shown to persist even after amyloid plaque reduction with therapies such as lecanemab. According to Elrifi, this evidence highlights a critical unmet need in Alzheimer's treatment: addressing residual neuroinflammation that may continue to drive disease progression. Intranasal foralumab is designed to modulate immune responses within the central nervous system and calm overactivated microglia, potentially reducing chronic inflammation associated with neurodegeneration. The intranasal delivery method is intended to provide targeted central nervous system exposure while minimizing systemic side effects. The Phase 2 study is a randomized, placebo-controlled trial assessing the safety, tolerability, and potential efficacy of intranasal foralumab in patients with early or mild Alzheimer's disease. Primary endpoints include changes in neuroinflammation as measured by TSPO-PET imaging, cognitive function outcomes, and biomarker changes related to amyloid and tau pathology. With the first patient now dosed, Tiziana Life Sciences advances into the next phase of clinical evaluation, positioning the company to generate meaningful data on whether addressing neuroinflammation—alone or in combination with anti-amyloid therapies—can improve outcomes for patients with early Alzheimer's disease. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #AlzheimersResearch #Neuroinflammation #BiotechNews #PETscan #ClinicalTrials #AlzheimersTreatment #PharmaUpdates #HealthcareInnovation

Before his symptoms began, Anthony and Karen Sanone were always on the move, traveling, working and staying active. A former college athlete who played football and baseball, Anthony spent more than 35 years as a chemical sales manager. Karen, a director of human resources at an education agency, now balances her professional role with caregiving. The couple documents their experiences on Anthony's Instagram account, @anthony_vs_alzheimers, and through their younger-onset caregiver community, Surviving the Now.In this conversation with Being Patient's Mark Niu, Anthony and Karen talk about the early warning signs and the long, often confusing road to a younger-onset Alzheimer's diagnosis. They discuss navigating work, pursuing treatment with Leqembi, managing seizures, and reshaping daily life around routines, travel strategies, and safety. Karen also shares candid advice on planning for the future, building a support system and finding ways to “live in the moment” and make meaningful memories, even as the disease progresses.-- If you loved listening to this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/Follow Being Patient: Twitter: https://twitter.com/Being_Patient_Instagram: https://www.instagram.com/beingpatientvoices/Facebook: https://www.facebook.com/beingpatientalzheimersLinkedIn: https://www.linkedin.com/company/being-patientBeing Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://www.beingpatient.com/category/video/

Steigende Sozialausgaben belasten Landkreis Darmstadt-Dieburg, Hessisches Landesmuseum findet neuen Pächter für Museumscafé und Kliniken in der Region bereiten Behandlung mit Alzheimer-Medikament vor. Das und mehr heute im Podcast. Alle Hintergründe zu den Nachrichten des Tages finden Sie hier: https://www.echo-online.de/lokales/kreis-darmstadt-dieburg/alsbach-haehnlein/krebskranker-junger-mann-ruft-zu-typisierungsaktion-auf-5176040 https://www.echo-online.de/lokales/darmstadt/neuer-paechter-fuer-cafe-im-hessischen-landesmuseum-5178195 https://www.echo-online.de/lokales/kreis-darmstadt-dieburg/landkreis-darmstadt-dieburg/wie-der-kreis-mit-der-soforthilfe-des-landes-umgeht-5192457 https://www.echo-online.de/lokales/darmstadt/darmstadts-esoc-rechnet-mit-eu-geldsegen-in-milliardenhoehe-5200168 https://www.echo-online.de/ratgeber/gesundheit/alzheimer-erste-patienten-bekommen-lecanemab-5179931 Ein Angebot der VRM.

Send us a textAlzheimer's disease is more than age-related memory loss—it's a serious brain disorder. In this episode of the Swiss Connection Science podcast, Swissinfo healthcare reporter Jessica Davis Pluess explores the science, hope, and controversy surrounding new Alzheimer's drugs like Leqembi and Kisunla. With billions invested and global regulatory decisions diverging, what do these treatments mean for patients and healthcare systems? Visit SWI swissinfo.ch for more on this topic and a video on this story. Please come to SWI swissinfo.ch for more of our science stories from Switzerland.Journalist: Jessica Davis PlüssHost: Jo FahyAudio editor/video journalist: Michele AndinaDistribution and Marketing: Xin ZhangSWI swissinfo.ch is a public service media company based in Bern, Switzerland.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the rapidly evolving landscape of the pharmaceutical and biotech sectors, where regulatory updates, strategic mergers, and scientific breakthroughs are continually reshaping the industry.Starting with Novo Nordisk's recent challenges, their newly acquired manufacturing facility in Indiana has been flagged by the FDA with an "Official Action Indicated" designation. This classification, being the most severe level of inspection categorization, potentially signals delays in production and collaboration with partners like Regeneron and Scholar Rock. Such regulatory hurdles underscore the vital importance of compliance in ensuring smooth supply chains and market availability of therapeutics. It's a stark reminder of how critical regulatory oversight is in maintaining quality assurance within pharmaceutical manufacturing.Meanwhile, Johnson & Johnson is navigating its own regulatory landscape by engaging with the Trump administration on drug pricing reforms. These discussions highlight the broader industry's ongoing efforts to adapt to evolving regulatory frameworks and market dynamics. By spinning off its orthopedics unit, J&J aims to sharpen its focus and drive growth in more strategic areas, illustrating a trend towards specialization as companies strive to align with market demands.In mergers and acquisitions news, BioCryst Pharmaceuticals has completed a significant $700 million acquisition of Astria Therapeutics. This move positions BioCryst to compete directly with Takeda's hereditary angioedema therapy, Takhzyro. The acquisition emphasizes the competitive nature of specialty markets and highlights how targeted acquisitions can expand therapeutic pipelines.Halozyme Therapeutics is similarly active in pursuing mergers and acquisitions to enhance its drug delivery capabilities. Their recent acquisition of Elektrofi aligns with Halozyme's strategy to innovate in drug delivery technologies, which are increasingly recognized for their role in improving therapeutic efficacy and patient experience.Funding models are also evolving within the industry as alternative programs for specialty drugs gain attention for their potential cost-saving benefits for self-insured employers. However, these models raise ethical concerns due to potential financial risks shifting onto patients. This ongoing debate underscores the complexity of balancing cost management with patient access in healthcare.BioNTech's initiative to establish mRNA vaccine production facilities in Africa represents a significant step towards enhancing vaccine accessibility and equity on a global scale. Supported by European Union funding, this move underscores the importance of regional manufacturing hubs in facilitating rapid distribution of life-saving vaccines.Turning our focus to clinical advancements, Roche and Eli Lilly's collaboration has led to FDA approval of an Alzheimer's blood test for primary care use. This diagnostic tool could significantly enhance the adoption of Alzheimer's treatments like Biogen's Leqembi by streamlining diagnosis processes in primary care settings.Novo Nordisk's Indiana facility has again made headlines due to FDA scrutiny, potentially impacting partnerships with major players such as Regeneron. This situation highlights how stringent compliance requirements can influence strategic partnerships and operational timelines.On a promising note, Kailera Therapeutics has raised $600 million in funding to advance its obesity treatment program into Phase 3 trials. With Bain Capital leading this round, it reflects investor confidence in targeting metabolic disorders—a growing area of focus given their widespread health implications.Artificial intelligence continues to reshape drug discovery processes. Takeda Pharmaceuticals' $1 Support the show

Originally from Argentina, educator and creative entrepreneur Laura Tobi, 58, moved to the U.S. 26 years ago. An educational designer by training, she has worked with labor unions, corporations, government, and public and private school systems, later founding a Miami-based business to cultivate creative thinking for learners of all ages. After years as a caregiver to her both husband and daughter through serious chronic illnesses, she and her husband relocated to North Carolina in 2024, where she noticed increased memory problems. A neurologist connected the dots: a lumbar puncture confirmed Alzheimer's, and further evaluation found epilepsy, revealing silent seizures. In this interview with Being Patient's Mark Niu, Tobi shares how she pairs Leqembi infusions with lifestyle changes inspired by the Ornish program — nutrition, exercise, stress management, and social support — while staying rooted in community through volunteering, teaching, improv, and clay sculpture in her home studio. Her takeaways: build community, stay mentally and physically active, advocate for yourself, and keep seeking joy — through teaching, volunteering, improv, and making art.—-If you loved listening to this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/Follow Being Patient: Twitter: https://twitter.com/Being_Patient_Instagram: https://www.instagram.com/beingpatientvoices/Facebook: https://www.facebook.com/beingpatientalzheimersLinkedIn: https://www.linkedin.com/company/being-patientBeing Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://www.beingpatient.com/category/video/

Ecoutez Ça va beaucoup mieux avec Jimmy Mohamed du 10 septembre 2025.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Ein neues Alzheimer-Medikament Leqembi kommt nach Deutschland. Die Therapie ist aufwändig. Zugleich ist das deutsche Gesundheitssystem überlastet. Das muss sich ändern, damit die Menschen das Medikament bekommen, die davon profitieren. Kohlenbach, Lukas www.deutschlandfunk.de, Wissenschaft im Brennpunkt

Kohlenbach, Lukas www.deutschlandfunk.de, Forschung aktuell

Pyritz, Lennart www.deutschlandfunk.de, Forschung aktuell

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Biogen's sales of the partnered Alzheimer's drug Leqembi have climbed 20% in the second quarter, while CEO Chris Viehbacher dismisses rumors of disagreements with Eisai. Moderna has cut 10% of its global workforce as part of cost-cutting measures. AbbVie is celebrating the success of Skyrizi and Rinvoq, Lilly's Mounjaro shows promise in a cardiovascular trial, and there is optimism around Sarnas for therapeutic breakthroughs. Amidst industry challenges, many biopharma professionals are looking for new job opportunities.

The Sarepta saga continued into another week as the FDA recommended that the voluntary hold on the company's Duchenne muscular dystrophy gene therapy be lifted for ambulatory patients, after determining that the death of an 8-year-old Brazilian Duchenne patient who had received Elevidys' was not caused by the drug.  Sarepta's stock has swung wildly and its transparency questioned after it elected not to reveal the death of a third patient—a participant in a trial of a gene therapy for limb girdle muscular dystrophy—during a business update last week.    Speaking of entities—or individuals—who have trouble staying out of the news, Health Secretary Robert F. Kennedy Jr. plans to dissolve the U.S. Preventive Services Task Force because it is “too woke.” Also on Monday, Kennedy addressed what he called the “broken” vaccine injury compensation program. Without offering details, he vowed to “fix” the U.S.'s VICP and return it to its “original Congressional intent.”   On the business side of the biopharma house, Q2 earnings are in full swing, with AstraZeneca announcing estimate-beating numbers and CEO Pascal Soriot saying the world “needs to share” in global pharma R&D, while Merck cut $3 billion to support an aggressive launch schedule. Meanwhile, a week ahead of its own earnings report, Novo Nordisk named a new CEO and lowered its 2025 sales guidance for the second time this year.   In clinical development, the Alzheimer's Association Annual Conference is underway in Toronto, with Roche's trontinemab the standout so far. In a Phase Ib/IIa trial, the next-gen anti-amyloid antibody rapidly cleared amyloid from the brains of patients with Alzheimer's disease after just seven months—besting the 18-month timeframe for Biogen and Eisai's Leqembi and Eli Lilly's Kisunla. While Leqembi and Kisunla have shown some progress is slowing down the progression of Alzheimer's, their effect size is modest and they don't work for all patients—leaving plenty of room for symptomatic treatments, such as those being developed by Bristol Myers Squibb and Acadia Pharmaceuticals. The space is gearing up for several readouts, for both symptomatic and disease-modifying therapies alike.   And in BioPharm Executive this week, we dig into the top VC rounds so far this year and highlight a few scrappy biotechs walking the solo road.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. GSK has entered a partnership with Hengrui worth up to $12 billion, focusing on the COPD candidate HRS-9821. The FDA's new voucher policy has caused confusion among experts, as it lacks clear definition and was announced without public input. The American Medical Association urges RFK Jr. to maintain the preventive task force, and Sarepta denies a patient death is linked to Elevidys as the FDA launches a probe. Biopharma companies are leaning towards holistic treatments for Alzheimer's, while Atai-partnered schizophrenia drug fails in a mid-stage trial. Boehringer partners with Irish startup Re-Vana in a $1 billion+ eye deal.As the Alzheimer's space becomes more competitive, biopharma companies are focusing on holistic treatments beyond disease-modifying drugs like Leqembi and Kisunla. Companies such as Bristol Myers Squibb, Acadia, Otsuka, and Lundbeck are renewing their search for symptomatic treatments. Five upcoming data drops could potentially lead to more effective therapies for Alzheimer's. Sarepta Therapeutics is facing challenges due to safety concerns surrounding its gene therapies, leading to a drop in stock value. The FDA's new voucher program aims to offer accelerated pathways for drugs meeting certain criteria, but experts criticize the lack of transparency and public input in the policy's announcement. Sarepta's future is uncertain as the FDA considers a new study for Elevidys, and the EU issues a negative opinion on the drug. Other news includes delays in the FDA decision on GSK's Blenrep, AstraZeneca's PIII win with nanobody treatment for myasthenia gravis, and the removal of thimerosal from influenza vaccines. George Tidmarsh has been appointed as the new chief of FDA's CDER.

Welcome back to Dementia Discussions! I'm so grateful to be back with you after a bit of a hiatus, and today's episode is a truly meaningful one. I sit down with Dr. Miriam Winthrop, an adult and geriatric psychiatrist whose compassionate approach and wealth of knowledge make her a true gem in the dementia care world. We open up about the recent fires that disrupted both our lives and how trauma and caregiving intersect—especially in these unpredictable times.This conversation dives deep into the emotional, medical, and behavioral complexities of dementia. Dr. Winthrop shares how she supports individuals from the early signs of cognitive decline to the later stages of dementia, helping both patients and their families manage symptoms, medication, and caregiving strategies. Whether you're navigating a new diagnosis or have been caregiving for years, this episode offers insight, validation, and practical tools for every step of the journey. Timeline Summary[1:33] – Introducing Dr. Miriam Winthrop and reconnecting after the LA fires[6:37] – How patients find their way to a geriatric psychiatrist and the signs of prodromal dementia[10:24] – The complexity of diagnosing mild cognitive impairment (MCI)[15:43] – Understanding MCI, psychiatric symptoms, and the role of early treatment[18:58] – Leqembi and considerations around early intervention and clinical trials[21:28] – Aricept, Namenda, and their behavioral uses in dementia care[28:15] – Behavioral challenges in moderate dementia and non-medication strategies[31:39] – Communicating creatively with loved ones using the DARE method[36:20] – What causes delirium and how to spot it in dementia patients[40:19] – The emotional toll and shifting family dynamics in the middle to later stages[45:41] – Acceptance, letting go of expectations, and redefining “normal”[47:57] – Medication tapering and palliative care considerations in late-stage dementia[51:57] – When hospice is involved and the importance of rational medication management Do you have a caregiving story to share? Barbara would love to hear from you! Please leave her a message at 310-362-8232 or send her an email through DementiaDiscussions.net. If you found value in today's episode, please don't forget to rate, follow, share, and leave a review. Your feedback helps us reach more listeners and continue producing this content.

On our Singapore Home Brew segment on the Saturday Mornings Show hosted by Glenn van Zutphen: In this episode, we delve into Singapore’s pivotal role in the global fight against Alzheimer’s disease, spotlighting the recent approval of LEQEMBI® by the Singapore Health Sciences Authority. Clinically proven to slow disease progression in early-stage patients, LEQEMBI® is a huge leap forward for treating symptoms and modifying the course of the disease in some patients. This milestone comes as more than 92,000 people in Singapore currently live with dementia, a number expected to rise sharply in the coming years. As the only Southeast Asian site in the international clinical trial, National University Hospital of Singapore played a key part in this breakthrough, with promising results confirmed in the Asian sub-analysis. Joining us to unpack this development are two leading voices in neurology and aging: Professor Christopher Chen, Visiting Consultant at National University Hospital and Director of the Memory, Ageing and Cognition Centre, and Associate Professor Adeline Ng, Senior Consultant in Neurology at the National Neuroscience Institute. They offer insights not just from a medical perspective, but also from the institutional frontlines where science meets healthcare policy and patient care. We explore how this treatment could transform the future for patients and caregivers in Singapore—offering more time, more clarity, and renewed hope.See omnystudio.com/listener for privacy information.

Listen in as our expert panel discusses medications for the treatment of Alzheimer dementia.  They'll review the risks and benefits of cholinesterase inhibitors, memantine, and the anti-amyloid monoclonal antibodies.  And you'll hear strategies for managing behavioral and psychological symptoms of dementia.   Special guests:Tatyana Gurvich, PharmD, BCGP, APhAssociate Professor of Clinical PharmacyMann USC School of PharmacyUCI Senior Health CenterCandace Pierce, DNP, RN, CNE, COINurse Educator, Nurse Planner, and Healthcare LeaderColibri HealthcareDarlene Moyer, MD, FAAFPAssociate Director, HonorHealth Family Medicine Residency ProgramAssociate Professor of Clinical Practice – SOMME – Arizona State UniversityClinical Associate Professor – University of Arizona College of Medicine - PhoenixYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in April 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: FAQ - Alzheimer Dementia Pharmacotherapy Chart – Pharmacotherapy of Dementia BehaviorsChart - Drugs with Anticholinergic ActivityChart - Send us a textCheck out our NEW podcasts.Rumor vs TruthYour trusted source for facts... where we dissect the evidence behind risky rumors and reveal clinical truths.Clinical CapsulesTRC editors break down the most impactful clinical developments - giving you clear, actionable takeaways in just minutes.If you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Pfizer stole the headlines this week with a pact worth up to $6 billion with Chinese biotech 3SBio for a PD-1/VEGF candidate just three months after inking a clinical trials collab for a similar drug with Summit Therapeutics. It's the largest Chinese licensing deal in recent memory, as pharmas continue to turn to the country to fill their pipelines.  Also on Tuesday, the Department of Health and Human Services offered a smidge more detail on President Donald Trump's Most Favored Nation executive order. A press release explained that drug prices will be tied to the lowest price in certain countries with a GDP at least 60% that of the U.S. and that the effort will focus on branded drugs.   Over at the FDA, the strategy around COVID-19 vaccines is evolving. According to an editorial published in the New England Journal of Medicine Tuesday by FDA Commissioner Marty Makary and CBER director Vinay Prasad, future COVID-19 approvals will focus on adults over 65 and high-risk individuals six months to 64 years old—a strategy they say will better align the U.S. with other high-income nations. This is also in sync with the Novavax approval, which came in Friday after a few delays.   Meanwhile, the FDA's Oncologic Drugs Advisory Committee (ODAC) is currently in the midst of a two-day meeting, but acquiring the necessary expertise was “absolute chaos,” according to an agency insider who spoke with BioSpace. This is partly due to the decimation of an FDA office that includes staff responsible for screening scientific and therapeutic area experts for conflicts of interest.  Going back to last week—which seems like a year ago at this point—we were somewhat shocked to learn that the CEO of one of the world's most valuable pharma companies is on his way out. Friday morning, Novo Nordisk announced that CEO Lars Fruergaard Jørgensen will be leaving the company after eight years at the helm. After peaking last June at about $155 apiece, the obesity leader's shares are currently worth just $68. Novo said the decision for Jorgensen to leave was mutual, but Jorgensen was not made available to speak on a call following the announcement.  Finally, a couple of milestones are worth noting: First, the Alzheimer's space got a big win on Friday when the FDA approved the first blood-based test for the disease—news that could be a boon to Eli Lilly's Kisunla and Biogen & Eisai's Leqembi. And second, a nine-month-old boy named KJ with a disease called CPS1 deficiency that affects just 1 in 1.3 million U.S. babies was treated with a single-use CRISPR treatment created just for him. It's an incredible story that highlights just how far gene editing has come, but it also highlights a rare disease crisis, with these sorts of ultra- and nanorare diseases lacking the necessary financial incentive to motivate biopharma's focus.   

Pushback against the Trump administration's massive government cuts exploded this weekend across America—and biopharma is no exception. Taking a deep dive into the leadership cuts, we found that more than half of the senior FDA leaders from six months ago are no longer there, and that's just the leadership. Across the Department of Health and Human Services, some 20,000 people will be leaving—of their own accord or otherwise—amounting to a 25% reduction in headcount that would leave HHS with around 62,000 employees. With many of these people likely destined for biopharma, does this pose an ethical problem?   Meanwhile, the escalating tariff war is beginning to ring alarm bells for the economy, with Goldman Sachs now predicting a 45% chance of a recession happening in the next 12 months. While pharma has historically been considered resistant to the challenges of a recession—people always need medicines—this time around could be different, in part because of the consumer-led obesity market. Thanks to the Trump administration's decision to nix a Biden era proposal to cover GLP-1s under Medicare Part D—at least for now—these drugs will continue to cost consumers a pretty penny.   Even without a recession being declared, Eli Lilly's and Novo Nordisk's stocks are falling significantly with the rest of the market. Lilly has lost more than $95 billion in market value in one month. Novo's value has declined $72 billion.   The drugmakers are also still battling makers of knockoff versions of their drugs. Most recently, Lilly filed a lawsuit against a med spa in Indianapolis for allegedly taking vials of tirzepatide and splitting them up into single doses that are sold to patients without the packaging inserts.  Of course, Lilly and Novo aren't the only pharma drug rivalry out there. There's also Keytruda vs. Opdivo, Leqembi vs. Kisunla and more.   Finally, we take a look at seven late-stage MASH candidates that could hit the market in the next few years, following the FDA's 2024 approval of Madrigal's Rezdiffra, the first treatment for the metabolic disorder. 

Biopharma's reaction to the forced resignation of venerable CBER director Peter Marks has been swift and furious, with former FDA Commissioner Robert Califf saying on LinkedIn that “the FDA as we've known it is finished.” Analysts, meanwhile, called Marks' exit “arguably biotech investors' greatest fear,” as company shares across the industry tumbled.   Marks' announcement added insult to injury for the agency, which was already reeling from the announced cuts of 10,000 employees across the Department of Health and Human Services, including 3,500 FDA staffers. Those layoffs began to roll out on Tuesday as some employees showed up to work only to discover they no longer had a job. Amid all this chaos, Cantor Fitzgerald analysts called for Kennedy himself to get the axe, saying in part that he was “undermining the trusted leadership of health care in this country.”    Despite the turmoil, drug development continues in the obesity space, with Novo Nordisk presenting mixed data from its semaglutide franchise at the American College of Cardiology's annual conference last weekend. While an oral version of the blockbuster drug showed cardiovascular benefits for some patients, it failed to change the trajectory of other major adverse cardiovascular events. Meanwhile, Novo continues its battle against compounding pharmacies manufacturing copycat versions of semaglutide—as multiple players scramble for a piece of this massive pie.    On the Alzheimer's front, Eli Lilly's Kisunla failed last week to win the recommendation of the EU's Committee for Medicinal Products for Human Use. This decision is consistent with CHMP's recent stance on anti-amyloid antibodies, as Biogen and Eisai have also struggled to get Leqembi approved in Europe.    On a positive note, pharma R&D returns grew again in 2024, but Deloitte warned that this progress is “fragile.” The firm urged companies to be bold and embrace cutting edge technology like gene therapy and AI. These returns can't help everyone, however, as the past week has seen an uptick in layoffs across biopharma, including at Carisma Therapeutics, Organon and Tenaya Therapeutics.   Finally, as April kicks off cancer conference season, BioSpace took a deep dive into the recent action in the always-hot in radiopharmaceuticals space.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The European Union has rejected Lilly's Alzheimer's drug Kisunla, citing potential risks of brain swelling and bleeding. This decision follows a similar rejection of a rival drug, Leqembi. Novo Nordisk is facing challenges in its weight loss business due to compounded versions of its drug Semaglutide making up a significant portion of the market. Milestone Pharmaceuticals experienced a setback when the FDA issued a complete response letter for its tachycardia drug Cardamyst. The company is now focusing on restructuring and streamlining operations.Merck's injectable Keytruda has shown promising results in a pivotal trial, and BioNTech's bispecific treatment has elicited positive responses in the majority of patients with small cell lung cancer. Novo Nordisk's stock dipped after disappointing weight loss results for Cagrisema, and Biogen and Eisai's drug Leqembi faced setbacks in the UK and Australia. In other news, United States Pharmacopeia is offering career opportunities in various fields including science, technology, regulatory affairs, and quality assurance. Stay tuned for more updates on the latest developments in the pharmaceutical and biotechnology industries.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. J&J has recently halted a late-stage depression trial due to lack of efficacy. Analysts do not believe this will have a significant impact on the company's broader neuroscience strategy. Meanwhile, there seems to be confusion at the FDA with terminations and reversals happening. In other news, Novo Nordisk has conducted limited studies on GLP-1s for addiction. Biogen and Eisai are facing setbacks with Leqembi overseas. There are potential FDA changes under commissioner Marty Makary. The FDA's priority review vouchers are in need of transparency. AstraZeneca has presented strong data for Imfinzi in stomach cancer. Atea Pharmaceuticals has made the decision to cut its workforce. Novo Nordisk is entering a legal battle against GLP-1 compounders, while Lilly has achieved a victory in a different matter. Pharmaceutical executives have recently shared insights on trust, technology, and the future at the WEF. Overall, there are various developments happening in the Pharma and Biotech industry that are worth keeping an eye on.

Are new Alzheimer's treatments finally offering hope? In this episode, we're diving into the latest breakthroughs in Alzheimer's treatment—what's been approved, what's in the pipeline, and what these medications can and cannot do. If you or a loved one are concerned about cognitive decline, this is an episode you don't want to miss!What to Listen For[02:28] – Why Alzheimer's research has been so challenging—did you know a major 2006 study was exposed as fraudulent?[03:59] – The amyloid plaque controversy—why has it dominated research for so long?[05:45] – Three alternative Alzheimer's theories that could reshape treatment: the Tau Hypothesis, Inflammation Hypothesis, and Environmental Toxicity Hypothesis.[09:04] – Why drug development takes so long—did you know it can take up to 30 years from research to standard treatment?[13:28] – The hard truth: We still have no cure, and no medication reverses Alzheimer's symptoms. So what do current drugs actually do?[14:08] – The most commonly prescribed Alzheimer's drugs—what they target and how they work.[16:05] – The new FDA-approved drugs Leqembi and Casenla—how they work, their risks, and why they're so expensive.[18:20] – The serious risks of new Alzheimer's treatments—brain swelling, bleeding, and the need for regular IV infusions.[20:30] – Why weight-loss drugs like Ozempic and Wegovy are now being studied for Alzheimer's prevention.[25:00] – The importance of early detection—why treatments work best when started as early as possible.While we don't yet have a cure for Alzheimer's, the latest treatments offer new possibilities for slowing cognitive decline. But with high costs, serious risks, and the need for early detection, it's crucial to stay informed. If you or a loved one are at risk, talk to your doctor about the latest research and what steps you can take today.Enjoyed this episode? Don't forget to subscribe, leave a review, and share this with someone who could benefit from the latest Alzheimer's research!RESOURCES: Book a FREE Discovery Call with Amy Lang Sign up for Mini-Intensive: Create Your Roadmap (90 minutes) Order Amy's book Thoughts Are Habits Too: Master Your Triggers, Free Yourself From Diet Culture, and Rediscover Joyful Eating. Join our private Facebook group: Moxie Club Meetup Follow Amy on Instagram @habitwhisperer

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Bristol Myers Squibb is seeking to broaden the use of its CAR T cell therapy, Breyanzi, to address marginal zone lymphoma as a strategy to offset losses from exclusivity. In other news, Boehringer Ingelheim has seen promising results in a Phase III trial for its lung fibrosis drug, randomilast, aimed at progressive pulmonary fibrosis. However, Pliant has experienced a stock decline following the halt of its Phase IIb/III study for idiopathic pulmonary fibrosis. Additionally, Vertex has received FDA approval for its non-opioid pain treatment, while AbbVie has secured approval for a new antibiotic. Bain's acquisition of Tanabe for $3.3 billion is also making headlines. Regeneron is currently in a legal battle with Sanofi over the Dupixent pact, and Equillium's itolizumab is undergoing testing against Humira for ulcerative colitis. On the horizon, Acelyrin and Alumis are joining forces to address immune-mediated diseases, while Eisai is seeking subq approval for Leqembi due to sluggish US sales. Job opportunities are available at ATCC, AbbVie, Regeneron Pharmaceuticals, and Dren Bio.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eisai reports lagging sales of Leqembi in the US and is now looking towards gaining approval for a subcutaneous version. Novo Nordisk executives are trying to boost sentiment after the failure of obesity candidate Cagrisema, without providing hard numbers. Regeneron is suing Sanofi for allegedly withholding information about the sales of Dupixent. Nasdaq newcomers Acelyrin and Alumis have merged to focus on immune-mediated diseases. The AAPS National Biotechnology Conference will cover trends in research and biopharma markets.Equillium's Itolizumab is competing with Humira in ulcerative colitis. FDA approval of Vertex's non-opioid Jornavx signals a new era in pain treatment. Novo's bispecific for hemophilia has aced a phase III pediatric trial. Lilly has increased Zepbound supply, prompting analysts to question if it is sustainable. BMS has added $2 billion to cost-cutting plans and is eyeing deals after the success of Cobenfy. AstraZeneca has axed two Alexion assets as Q4 earnings exceed expectations.

Ozempic gains expanded approval; MS treatment gets Boxed Warning added to label; Monotherapy approval granted for treatment resistant depression Tx Spravato; Leqembi gains  maintenance regimen; Enhertu gains new Breast CA indication.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sage has rejected Biogen's unsolicited buyout offer and will seek strategic alternatives. Biogen and Eisai have received approval for a monthly maintenance regimen for Alzheimer's drug Leqembi. Veru's drug has shown promise in sparing lean mass in overweight adults on Wegovy. The Duchenne muscular dystrophy space is on the verge of a pivotal era with several companies developing investigational therapies. Akero has rebounded in a mid-stage trial, Daiichi Sankyo is optimistic for 2025, and Allakos is cutting its workforce. The text discusses the advancements in the Duchenne Muscular Dystrophy (DMD) space as it enters a pivotal era, with companies such as Capricor Therapeutics, Wave Life Sciences, and RegenxBio working on investigational therapies to address unmet needs. It also mentions Daiichi Sankyo's recent success with the approval of Astrazeneca-partnered Dato-DXD. Additionally, new treatments are in development for Achondroplasia to challenge Biomarin's Voxzogo. Novo's obesity drug shows promising results, Merck's Keytruda combo fails in a Phase III trial for GI cancer, and Tris Pharma wins late-stage for a non-opioid painkiller. The text also invites feedback from readers on topics they would like to see covered in the future.

Dr. K speaks with Alzheimer's expert Jason Karlawish, MD, about the new anti-amyloid Alzheimer's medications lecanemab (Leqembi) and donanemab (Kisunla). They discuss how biomarkers have changed diagnosing Alzheimer's disease, how well these new drugs work, and much more.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Amgen's obesity candidate, maritide, faced new safety concerns related to bone density, causing a drop in the company's stock. Biogen's shares have also plummeted due to issues such as a slow launch for their Alzheimer's medicine and a lackluster pipeline. Meanwhile, the biotech company Metsera raised significant funds for their long-acting GLP-1 drug despite competition in the weight loss space. Additionally, Kezar's autoimmune drug faced a second FDA clinical hold, and Syros experienced a significant drop in stock value due to a late-stage MDS failure. Novo's deal with Catalent is seen as a significant moment for the CDMO sector. These developments indicate ongoing challenges and opportunities in the biotech industry.Biogen's shares have dropped by 36% in 2024 due to factors such as a slow launch for Alzheimer's medicine Leqembi and a lackluster pipeline. The Novo-Catalent deal is seen as a defining moment for the CDMO industry, with concerns about consolidation limiting competition but also providing opportunities for smaller-scale CDMDs to find new partners. Other news includes Amgen facing bone density safety concerns for Maritide, AbbVie shares plummeting due to a failed schizophrenia asset, and Bayer's CEO admitting that their earnings are not looking good. In the biopharma job market, positions such as Executive Director of Biologics Analytical Research and Development at Merck & Co. and Vice President of Global Program Head - Ophthalmology at Regeneron Pharmaceuticals are available.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Eisai's sales of its Alzheimer's disease therapy Leqembi have disappointed analysts, leading the company to lower its fiscal 2024 guidance. The underwhelming sales are attributed to barriers such as coverage, infusion centers, and time to diagnosis. In other news, Pfizer has made a $1 billion commitment in China to boost innovation and target the Chinese market, while AstraZeneca's China head has been taken into custody by Chinese authorities for reasons that remain unclear. There is also a dispute between Lilly and Novo over Catalent's GLP-1 work, as regulators review Novo Holdings' buyout of Catalent and the work the contract drug manufacturer may or may not be performing for Eli Lilly remains contentious.Additionally, a gene therapy webinar on successful preparation for scaling gene therapy processes is highlighted. Other news includes the impact of a Trump victory on the biopharma industry, cell therapy biotechs shifting focus to autoimmune expertise, and updates on Lilly's Q3 performance and more.

It's too soon to conclude anti-amyloid therapies are safe for use by Alzheimer's patients in the real world, even as early reports are encouraging, argues BioCentury Executive Editor Selina Koch on the latest BioCentury This Week podcast. Koch and colleagues discuss takeaways from this year's Clinical Trials on Alzheimer's Disease annual meeting, including conclusions from adverse event data for Leqembi lecanemab and what the true test of appropriate use and safety for the drug might look like.BioCentury's editors also assess Phase II data presented at CTAD by UCB that provide some of the first clues about what species of tau to target and in which patients. And they discuss what results of Tuesday's presidential contest in the U.S. will mean for FDA, as well as the state of play for China biotech as the industry continues to grind out its first bear market.View full story: https://www.biocentury.com/article/65407500:00 - Introduction01:23 - CTAD: Anti-amyloids14:22 - CTAD: UCB's tau data19:47 - FDA & the Election28:16 - China Summit DebriefTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

A substantial part of the biopharma ecosystem involves deals between biotechs and academics, with smaller companies accessing assets to add to their pipelines and technologies to help solve problems. On the latest BioCentury This Week podcast, BioCentury's editors discuss the interplay of biotech and academia, including how deals between the groups often come outside the hubs of Boston and the Bay Area and what types of indications and technologies are common focus points. They also discuss new data in Alzheimer's for Leqembi from Eisai and Biogen that provide insight into how to get the most out of anti-amyloid mAbs for the disease, and what's next for James Wilson now that the gene therapy pioneer is moving on from the University of Pennsylvania.View full story: https://www.biocentury.com/article/65317400:00 - Intro04:25 - Biotech-Academia Deals12:04 - Leqembi's Latest Data19:20 - What's Next for James Wilson

Audio roundup of selected biopharma industry content from Scrip over the business week ended 2 August 2024. In this episode: Pfizer bullish on its oral GLP-1; BMS's rising confidence about Medicare pricing of Eliquis; more long term data for Leqembi; NewAmsterdam's CETP inhibitor shows promise; and a look at Mankind's Bharat Serums buy. https://scrip.citeline.com/SC150698/Quick-Listen-Scrips-Five-MustKnow-Things Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Europe's CHMP has again ruled in contrast to FDA for a neurology product, this time on Biogen and Eisai's Leqembi for Alzheimer's disease. On the latest BioCentury This Week podcast, BioCentury editors discuss the similarities and differences between Leqembi lecenamab and Aduhelm aducanumab, the first anti-amyloid mAb from Biogen and Eisai and what it means for the next in line from that class, Kisunia donanemab from Eli Lilly. The editors also break down last week's ODAC meeting, which discussed trials in perioperative cancer for checkpoint inhibitors, and talk about the looming delay in reauthorization of the rare pediatric priority review voucher program. They also assess the implications of the investigation by the House Select Committee on the Chinese Communist Party into clinical trials run in Chinese military hospitals and the Xinjiang Uyghur Autonomous region, a story broken last week by Washington Editor Steve Usdin.View full story: https://www.biocentury.com/article/65301002:06 - CHMP Leqembi Decision09:53 - Perioperative Cancer17:45 - Pediatric Review Vouchers 23:55 - Beyond Biosecure

Dr. Zahydie L. Burgos Ribot cares for her husband, Francisco, also known as Paco, who is living with Young Onset Familial Alzheimer's Disease. In this episode, Zahydie and Paco share their caregiving journey. They talk about how they took time to understand and cope with Paco's diagnosis and process their feelings of grief before telling others. They also discuss Paco's treatment, including E2814 therapy and Leqembi medication, which help slow down Paco's Alzheimer's. And they talk about how they focus on living each day with intention and are enjoying crossing off things from their bucket list. Show notes with product and resource links: https://bit.ly/HHCPod184 Receive the podcast in your email here: http://bit.ly/2G4qvBv Order a copy of Elizabeth's book Just for You: a Daily Self Care Journal: http://bit.ly/HHCjournal For podcast sponsorship opportunities contact Elizabeth: https://happyhealthycaregiver.com/contact-us/ The Happy Healthy Caregiver podcast is part of the Whole Care Network. Rate and Review the podcast: https://bit.ly/HHCPODREVIEW

In the past few years pharmaceutical companies have developed a string of new Alzheimer's drugs called anti-amyloids, which target amyloid plaques in patients' brains. These plaques are one of the key biomarkers of the disease.The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.From the outside looking in, these Alzheimer's drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania's Perelman School of Medicine, and co-director of the Penn Memory Center.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Dr. K explains mild cognitive impairment (MCI) and discusses scientifically tested approaches to treating this memory condition, including the role of medications, supplements, hearing support, Leqembi and more.

Our guest on the podcast today is Howard Gleckman. He is the author of a book called Caring for Our Parents and an expert on the topic of aging and caregiving. Howard is also a senior fellow at the Urban Institute where he is affiliated with the Tax Policy Center and the Program on Retirement Policy. He also writes a tax and budget policy blog called TaxVox, which is available at Forbes.com. Before joining the Urban Institute, he was a senior correspondent in the Washington Bureau of Businessweek.BackgroundBioUrban InstituteTaxVox blogCaring For Our Parents, by Howard GleckmanLong-Term Care and Cognitive Decline“Is Long-Term Care a Predictable Need, or an Unexpected One?” by Howard Gleckman, Forbes.com, April 15, 2022.“The U.S. Needs to Help Seniors and Their Families Navigate Long-Term Care,” by Howard Gleckman, Forbes.com, Oct. 11, 2022.“The Quiet Struggles With Those Living Alone With Memory Loss,” by Howard Gleckman, Forbes.com, July 18, 2023.“Which States Provide the Best—and Worst—Long-Term Care Services?” by Howard Gleckman, howardgleckman.com, Oct. 2, 2023.“Why Are Care Delivery Models for People With Dementia Developing so Slowly?” by Howard Gleckman, howardgleckman.com, June 27, 2023.“FDA Has Approved the Anti-Alzheimer's Drug, Leqembi. What You Need to Know,” by Howard Gleckman, howardgleckman.com, July 6, 2023.“Experts Raise Questions About the Safety of Anti-Alzheimer's Drug Leqembi,” by Howard Gleckman, howardgleckman.com, April 25, 2023.“Aging in Place Is all the Rage, But It's Not Easy,” by Howard Gleckman, Forbes.com, March 21, 2022.Cost of Care“Medicaid Will Pay for a Common Alzheimer's Test But It May Not Be Reliable,” by Howard Gleckman, howardgleckman.com, Jan. 9, 2024.“Why Medicare Is Right to Negotiate Drug Prices,” by Howard Gleckman, howardgleckman.com, Aug. 30, 2023.“The Biggest Barrier to New Anti-Alzheimer's Drugs May Be Cost, Not Medicare Rules,” by Howard Gleckman, howardgleckman.com, June 14, 2023.“The War Over Whether Medicare Should Pay for new Anti-Alzheimer's Drugs,” by Howard Gleckman, howardgleckman.com, May 17, 2023.“The U.S. Predicts Big Increases in Skilled Nursing and Long-Term Care Costs,” by Howard Gleckman, howardgleckman.com, April 14, 2023.“Should You Enroll in a Medicare Advantage Plan?” by Howard Gleckman, howardgleckman.com, Nov. 1, 2022.Government and Policy“CMS' New Transparency Rule Can Help ‘Weed Out a Few Bad Actors' but Won't Impact Deals Much, Other Factors at Play,” by Shelby Grebbin, skillednursingnews.com, Dec. 6, 2023.“Forbes' Gleckman: Biden's PE Ownership Scrutiny Is ‘Two Beats Behind,'” by Amy Stulick, skillednursingnews.com, April 28, 2022.“Who Really Owns Nursing Homes, and How the Feds Are About to Learn More,” by Howard Gleckman, howardgleckman.com, Nov. 27, 2023.“Should State Long-Term Care Insurance Funds Invest in Stocks?” by Howard Gleckman, howardgleckman.com, June 22, 2023.Caregivers“Forget National Caregivers Month. Think About What Family Caregivers Need,” by Howard Gleckman, howardgleckman.com, Nov. 7, 2023.“For the First Time, Traditional Medicare Will Pay to Support Family Caregivers,” by Howard Gleckman, howardgleckman.com, Aug. 23, 2023.OtherLotsa Helping HandsMedicare.govFive-Star Quality Rating System